What is HC Wainwright’s Estimate for CRBU FY2026 Earnings?

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Caribou Biosciences in a research note issued to investors on Tuesday, September 23rd. HC Wainwright analyst R. Burns forecasts that the company will earn ($1.63) per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Separately, Wall Street Zen upgraded Caribou Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 24th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Caribou Biosciences presently has an average rating of “Buy” and an average target price of $6.67.

Caribou Biosciences Stock Performance

NASDAQ:CRBU opened at $2.13 on Wednesday. The company has a market cap of $198.35 million, a PE ratio of -1.20 and a beta of 2.54. Caribou Biosciences has a 52-week low of $0.66 and a 52-week high of $3.00. The stock has a 50-day simple moving average of $1.94 and a 200 day simple moving average of $1.36.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. The firm had revenue of $2.67 million for the quarter, compared to the consensus estimate of $1.64 million. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.

Institutional Trading of Caribou Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of CRBU. Cambridge Investment Research Advisors Inc. bought a new position in shares of Caribou Biosciences in the first quarter valued at $559,000. Aberdeen Group plc lifted its stake in Caribou Biosciences by 118.3% in the second quarter. Aberdeen Group plc now owns 897,579 shares of the company’s stock valued at $1,131,000 after acquiring an additional 486,435 shares during the last quarter. AQR Capital Management LLC lifted its stake in Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock valued at $480,000 after acquiring an additional 463,391 shares during the last quarter. Two Sigma Advisers LP grew its position in shares of Caribou Biosciences by 39.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company’s stock valued at $2,338,000 after acquiring an additional 416,600 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in shares of Caribou Biosciences during the 4th quarter worth about $649,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.